Business
Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
—Data updates to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD — CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\n—Data updates to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD —\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, will host an in-person Investor and Analyst Event in Atlanta that will simultaneously be webcast on Tuesday, Dec. 14, 2021, at 7:30 a.m. ET to discuss updates from three of the Company’s lentiviral vector (LVV)-based gene therapy programs: RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I), RP-L102 for Fanconi Anemia (FA) and RP-L301 for Pyruvate Kinase Deficiency (PKD). Clinical data for all three trials will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting being held Dec. 11-14, 2021.\n\nInvestors may register to attend the event in person by emailing [email protected]. A simultaneous webcast of the event and the presentation will be available under “Events” in the Investors section of the Company’s website at: https://ir.rocketpharma.com/.\n\nThe webcast replay will be available on the Rocket website upon completion of the event. This meeting is NOT an official program of the ASH annual meeting.\n\nAbout Rocket Pharmaceuticals, Inc.\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (A...